A recently published randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced NSCLC [14] was the first to study the chemotherapy selection based on marker status. Here, ERCC1 is linked to non-small cell lung carcinoma.